Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Prices for incoming sickle cell disease gene therapies from Vertex Pharmaceuticals Inc (NASDAQ:VRTX)/CRISPR Therapeutics AG (NASDAQ:CRSP), dubbed exagamglogene autotemcel (exa-cel), and Bluebird bio Inc’s (NASDAQ:BLUE) lovotibeglogene autotemcel (lovo-cel) at $2 million could be cost-effective under some scenarios.
- Although “these gene therapies have an incremental cost-effectiveness that is above commonly cited thresholds from the health care system perspective.”
- The analysis comes from a U.S. drug pricing group, Institute for Clinical and Economic Review (ICER).
- Results showed that at the placeholder price of $2 million per treatment course for lovo-cel or exacel (to be paid upfront), 15.4% of people (N=385 people per year) could be treated over five years without crossing the ICER budget impact threshold of $777 million per year.
- Also Read: Newly Approved Drugs In US Command Over $200,000 On An Average.
- Similarly, 33.9%, 24.7%, and 19.4% could be treated with either lovo-cel or exa-cel without reaching the potential budget impact threshold at the three threshold prices (approximately $0.90 million, $1.24 million, and $1.58 million per treatment).
- “The draft cost-effectiveness findings were driven by the lifetime opportunity to improve health and reduce VOC-related and other SCD-related costs, and to improve productivity and reduce caregiver costs in the modified societal perspective,” ICER said.
- Bluebird Bio signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release.
- Vertex and CRISPR completed the rolling Biologics License Applications to the FDA for (exa-cel) for sickle cell disease and transfusion-dependent beta-thalassemia.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!